Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 3.266
Filtrar
1.
Int J Biol Macromol ; 267(Pt 1): 131690, 2024 May.
Artículo en Inglés | MEDLINE | ID: mdl-38688790

RESUMEN

In the current study, how pectin retards the digestibility of wheat gluten was investigated using a static in vitro gastric-duodenal model. The degree of protein hydrolysis was estimated using the o-phthaldialdehyde method, while the in vitro digestograms were mathematically fitted using a single first-order kinetics model. Peptides' profile, free amino acids compositions, gluten-pectin interactions and their effects on enzymatic activities of proteolytic enzymes as well as on the gluten secondary structures under digestive conditions were studied using combined techniques. Results showed that pectin could retard gluten digestibility through 1). preferential absorption to insoluble gluten aggregates by electrostatic interactions; 2). increasing the helix and reducing the ß-sheet content of the solubilized gluten protein fractions in terms of their secondary molecular structures; 3). reducing pepsin activity by forming negatively charged pectin-gluten mixtures which then interacted with the positively charged pepsin molecules. The deeper insight into gluten-pectin interactions and their influences on gluten digestibility under gastrointestinal conditions provides important clues for developing effective forms of dietary fiber to improve the nutritional benefits of plant protein in individuals.


Asunto(s)
Digestión , Glútenes , Pectinas , Pepsina A , Pectinas/química , Pectinas/farmacología , Glútenes/química , Digestión/efectos de los fármacos , Hidrólisis , Pepsina A/química , Pepsina A/metabolismo , Duodeno/metabolismo , Duodeno/efectos de los fármacos , Triticum/química , Proteolisis , Aminoácidos/química , Cinética
2.
Dig Dis Sci ; 67(1): 224-232, 2022 01.
Artículo en Inglés | MEDLINE | ID: mdl-33534012

RESUMEN

BACKGROUND: Proton pump inhibitor (PPI) use is extremely common. PPIs have been suggested to affect the gut microbiome, and increase risks of Clostridium difficile infection and small intestinal bacterial overgrowth (SIBO). However, existing data are based on stool analyses and PPIs act on the foregut. AIMS: To compare the duodenal and stool microbiomes in PPI and non-PPI users. METHODS: Consecutive subjects presenting for upper endoscopy without colonoscopy were recruited. Current antibiotic users were excluded. Subjects taking PPI were age- and gender-matched 1:2 to non-PPI controls. Subjects completed medical history questionnaires, and duodenal aspirates were collected using a validated protected catheter. A subset also provided stool samples. Duodenal and stool microbiomes were analyzed by 16S rRNA sequencing. RESULTS: The duodenal microbiome exhibited no phylum-level differences between PPI (N = 59) and non-PPI subjects (N = 118), but demonstrated significantly higher relative abundances of families Campylobacteraceae (3.13-fold, FDR P value < 0.01) and Bifidobacteriaceae (2.9-fold, FDR P value < 0.01), and lower relative abundance of Clostridiaceae (88.24-fold, FDR P value < 0.0001), in PPI subjects. SIBO rates were not significantly different between groups, whether defined by culture (> 103 CFU/ml) or 16S sequencing, nor between subjects taking different PPIs. The stool microbiome exhibited significantly higher abundance of family Streptococcaceae (2.14-fold, P = 0.003), and lower Clostridiaceae (2.60-fold, FDR P value = 8.61E-13), in PPI (N = 22) versus non-PPI (N = 47) subjects. CONCLUSIONS: These findings suggest that PPI use is not associated with higher rates of SIBO. Relative abundance of Clostridiaceae was reduced in both the duodenal and stool microbiomes, and Streptococcaceae was increased in stool. The clinical implications of these findings are unknown.


Asunto(s)
Síndrome del Asa Ciega , Infecciones por Clostridium , Duodeno , Heces/microbiología , Intestino Delgado/microbiología , Inhibidores de la Bomba de Protones , Biopsia con Aguja/métodos , Síndrome del Asa Ciega/diagnóstico , Síndrome del Asa Ciega/epidemiología , Infecciones por Clostridium/diagnóstico , Infecciones por Clostridium/epidemiología , Duodeno/efectos de los fármacos , Duodeno/microbiología , Duodeno/patología , Femenino , Microbioma Gastrointestinal/efectos de los fármacos , Humanos , Masculino , Persona de Mediana Edad , Resultados Negativos , Inhibidores de la Bomba de Protones/administración & dosificación , Inhibidores de la Bomba de Protones/efectos adversos , Factores de Riesgo , Estados Unidos/epidemiología
3.
Cells ; 10(12)2021 12 14.
Artículo en Inglés | MEDLINE | ID: mdl-34944038

RESUMEN

Psychological stress increases the risk of gastrointestinal (GI) tract diseases, which involve bidirectional communication of the GI and nerves systems. Acute stress leads to GI ulcers; however, the mechanism of the native cellular protection pathway, which safeguards tissue integrality and maintains GI homeostasis, remains to be investigated. In a mouse model of this study, restraint stress induced GI leakage, abnormal tight junction protein expression, and cell death of gut epithelial cells. The expression of activating transcription factor 3 (ATF3), a stress-responsive transcription factor, is upregulated in the GI tissues of stressed animals. ATF3-deficient mice displayed an exacerbated phenotype of GI injuries. These results suggested that, in response to stress, ATF3 is part of the native cellular protective pathway in the GI system, which could be a molecular target for managing psychological stress-induced GI tract diseases.


Asunto(s)
Factor de Transcripción Activador 3/metabolismo , Enfermedades Gastrointestinales/etiología , Restricción Física , Estrés Psicológico/complicaciones , Factor de Transcripción Activador 3/deficiencia , Animales , Caspasa 3/metabolismo , Duodeno/efectos de los fármacos , Duodeno/metabolismo , Células Epiteliales/efectos de los fármacos , Células Epiteliales/metabolismo , Enfermedades Gastrointestinales/sangre , Regulación de la Expresión Génica , Ratones Endogámicos C57BL , Ratones Noqueados , Inhibidores de la Bomba de Protones/farmacología , ARN Mensajero/genética , ARN Mensajero/metabolismo , Estrés Psicológico/sangre , Proteínas de Uniones Estrechas/genética , Proteínas de Uniones Estrechas/metabolismo
4.
Int J Mol Sci ; 22(24)2021 Dec 19.
Artículo en Inglés | MEDLINE | ID: mdl-34948413

RESUMEN

Proton pump inhibitors (PPI) may improve symptoms in functional dyspepsia (FD) through duodenal eosinophil-reducing effects. However, the contribution of the microbiome to FD symptoms and its interaction with PPI remains elusive. Aseptic duodenal brushings and biopsies were performed before and after PPI intake (4 weeks Pantoprazole 40 mg daily, FD-starters and controls) or withdrawal (2 months, FD-stoppers) for 16S-rRNA sequencing. Between- and within-group changes in genera or diversity and associations with symptoms or duodenal factors were analyzed. In total, 30 controls, 28 FD-starters and 19 FD-stoppers were followed. Mucus-associated Porphyromonas was lower in FD-starters vs. controls and correlated with symptoms in FD and duodenal eosinophils in both groups, while Streptococcus correlated with eosinophils in controls. Although clinical and eosinophil-reducing effects of PPI therapy were unrelated to microbiota changes in FD-starters, increased Streptococcus was associated with duodenal PPI effects in controls and remained higher despite withdrawal of long-term PPI therapy in FD-stoppers. Thus, duodenal microbiome analysis demonstrated differential mucus-associated genera, with a potential role of Porphyromonas in FD pathophysiology. While beneficial effects of short-term PPI therapy were not associated with microbial changes in FD-starters, increased Streptococcus and its association with PPIeffects in controls suggest a role for duodenal dysbiosis after long-term PPI therapy.


Asunto(s)
Duodeno/microbiología , Disbiosis/inducido químicamente , Dispepsia/tratamiento farmacológico , Inhibidores de la Bomba de Protones/uso terapéutico , Adulto , Duodeno/efectos de los fármacos , Disbiosis/microbiología , Dispepsia/microbiología , Femenino , Microbioma Gastrointestinal/efectos de los fármacos , Humanos , Masculino , Persona de Mediana Edad , Porphyromonas/efectos de los fármacos , Inhibidores de la Bomba de Protones/efectos adversos , Adulto Joven
5.
Nutrients ; 13(10)2021 Sep 22.
Artículo en Inglés | MEDLINE | ID: mdl-34684302

RESUMEN

As part of a whole egg, egg white proteins are embedded in a lipid matrix that could modify their presentation to the immune system and their allergenic properties. The present study examines the impact of the main egg lipid components, triacylglycerides and phospholipids, in the early events of sensitization to egg. To this end, BALB/c mice were exposed intragastrically to egg lipids and egg lipid fractions, alone and in mixtures with egg white proteins, and Th2-promoting and proinflammatory effects were investigated. Our results highlight that the egg lipid fraction is responsible for Th2 adjuvant effects and point at a different influence of triacylglycerides and phospholipids on the bioavailability and immunomodulating properties of egg white proteins. While triacylglycerides promote type 2 responses at the small intestine level, phospholipids reduce the solubility of EW proteins and induce Th2 skewing in lymphoid intestinal tissues, which may have a direct impact on the development of egg allergy.


Asunto(s)
Proteínas del Huevo/farmacología , Yema de Huevo/química , Inmunización , Fosfolípidos/farmacología , Triglicéridos/farmacología , Animales , Pollos , Duodeno/efectos de los fármacos , Duodeno/metabolismo , Femenino , Regulación de la Expresión Génica/efectos de los fármacos , Intestino Delgado/metabolismo , Linfocitos/efectos de los fármacos , Linfocitos/metabolismo , Ratones Endogámicos BALB C , Solubilidad , Linfocitos T/efectos de los fármacos , Linfocitos T/metabolismo
6.
Nutrients ; 13(10)2021 Sep 23.
Artículo en Inglés | MEDLINE | ID: mdl-34684313

RESUMEN

Peptic ulcer episodes cause damage to the stomach and intestine, with inflammatory cell infiltration and oxidative stress as the main players. In this study, we investigated the potential of anthocyanidin malvidin for preventive and curative peptic ulcer treatment. The anthocyanidin effects were examined in gastric ulcer mouse models induced by ethanol, non-steroidal anti-inflammatory drugs (NSAIDs), ischemia-reperfusion (IR), acetic acid and duodenal ulcer induced by polypharmacy. Expression levels of oxidative and inflammatory genes were measured to investigate the mechanism of anthocyanin activity. At a dose of 5 mg·kg-1, Malvidin prevented gastric ulcer induction by ethanol, NSAID and repaired the tissue after 6 days of IR. Moreover, the anthocyanidin accelerated the healing of acetic acid-induced ulcer, increased the gene expression of EGF and COX-1, and downregulated MMP-9. Anthocyanin treatment mitigated the effect of polypharmacy on inflammation and oxidative stress observed in the intestine. Additionally, the compound downregulated cytokine expression and TLR4 and upregulated HMOX-1 and IL-10, exhibiting protective activity in the mouse gut. Malvidin thus prevented gastric and duodenal ulcers due to prominent anti-inflammatory and antioxidative effects on the gastrointestinal tract that were related to gene expression modulation and an increase in endogenous defense mechanisms.


Asunto(s)
Antocianinas/uso terapéutico , Inflamación/complicaciones , Inflamación/tratamiento farmacológico , Estrés Oxidativo , Úlcera Péptica/complicaciones , Úlcera Péptica/tratamiento farmacológico , Sustancias Protectoras/uso terapéutico , Ácido Acético , Animales , Antocianinas/farmacología , Antioxidantes/metabolismo , Biomarcadores/metabolismo , Ciclooxigenasa 1/genética , Ciclooxigenasa 1/metabolismo , Modelos Animales de Enfermedad , Duodeno/efectos de los fármacos , Duodeno/patología , Factor de Crecimiento Epidérmico/genética , Factor de Crecimiento Epidérmico/metabolismo , Etanol , Mucosa Gástrica/efectos de los fármacos , Mucosa Gástrica/patología , Regulación de la Expresión Génica/efectos de los fármacos , Indometacina , Inflamación/genética , Masculino , Metaloproteinasa 9 de la Matriz/genética , Metaloproteinasa 9 de la Matriz/metabolismo , Ratones , Estrés Oxidativo/efectos de los fármacos , Estrés Oxidativo/genética , Úlcera Péptica/genética , Úlcera Péptica/inmunología , Polifarmacia , Sustancias Protectoras/farmacología , Daño por Reperfusión/complicaciones , Daño por Reperfusión/tratamiento farmacológico , Daño por Reperfusión/patología , Úlcera Gástrica/inducido químicamente , Úlcera Gástrica/tratamiento farmacológico , Úlcera Gástrica/genética , Úlcera Gástrica/inmunología , Uniones Estrechas/efectos de los fármacos , Uniones Estrechas/metabolismo , Cicatrización de Heridas/efectos de los fármacos
7.
Toxicol Appl Pharmacol ; 433: 115773, 2021 12 15.
Artículo en Inglés | MEDLINE | ID: mdl-34688701

RESUMEN

Carcinogenicity of hexavalent chromium [Cr (VI)] has been supported by a number of epidemiological and animal studies; however, its carcinogenic mode of action is still incompletely understood. To identify mechanisms involved in cancer development, we analyzed gene expression data from duodena of mice exposed to Cr(VI) in drinking water. This analysis included (i) identification of upstream regulatory molecules that are likely responsible for the observed gene expression changes, (ii) identification of annotated gene expression data from public repositories that correlate with gene expression changes in duodena of Cr(VI)-exposed mice, and (iii) identification of hallmark and oncogenic signature gene sets relevant to these data. We identified the inactivated CFTR gene among the top scoring upstream regulators, and found positive correlations between the expression data from duodena of Cr(VI)-exposed mice and other datasets in public repositories associated with the inactivation of the CFTR gene. In addition, we found enrichment of signatures for oncogenic signaling, sustained cell proliferation, impaired apoptosis and tissue remodeling. Results of our computational study support the tumor-suppressor role of the CFTR gene. Furthermore, our results support human relevance of the Cr(VI)-mediated carcinogenesis observed in the small intestines of exposed mice and suggest possible groups that may be more vulnerable to the adverse outcomes associated with the inactivation of CFTR by hexavalent chromium or other agents. Lastly, our findings predict, for the first time, the role of CFTR inactivation in chemical carcinogenesis and expand the range of plausible mechanisms that may be operative in Cr(VI)-mediated carcinogenesis of intestinal and possibly other tissues.


Asunto(s)
Transformación Celular Neoplásica/inducido químicamente , Cromo/toxicidad , Regulador de Conductancia de Transmembrana de Fibrosis Quística/genética , Neoplasias Duodenales/inducido químicamente , Duodeno/efectos de los fármacos , Silenciador del Gen/efectos de los fármacos , Proteínas Supresoras de Tumor/genética , Contaminantes Químicos del Agua/toxicidad , Administración Oral , Animales , Transformación Celular Neoplásica/genética , Transformación Celular Neoplásica/metabolismo , Transformación Celular Neoplásica/patología , Cromo/administración & dosificación , Regulador de Conductancia de Transmembrana de Fibrosis Quística/metabolismo , Bases de Datos Genéticas , Agua Potable , Neoplasias Duodenales/genética , Neoplasias Duodenales/metabolismo , Neoplasias Duodenales/patología , Duodeno/metabolismo , Duodeno/patología , Perfilación de la Expresión Génica , Ratones , Medición de Riesgo , Biología de Sistemas , Transcriptoma , Proteínas Supresoras de Tumor/metabolismo , Contaminantes Químicos del Agua/administración & dosificación
8.
Hepatol Commun ; 5(12): 2139-2150, 2021 12.
Artículo en Inglés | MEDLINE | ID: mdl-34558857

RESUMEN

Hepcidin is a liver-derived peptide hormone that limits iron egress from tissues to the bloodstream. It operates by binding to the iron exporter ferroportin, which blocks iron transport and tags ferroportin for degradation. Genetic hepcidin inactivation leads to hereditary hemochromatosis, a disease of iron overload. We used wild-type and Hjv-/- mice, a model of hemochromatosis, to examine the expression of ferroportin and other proteins of iron metabolism in hepcidin target tissues. The animals were previously subjected to dietary iron manipulations. In Hjv-/- mice, hepcidin messenger RNA correlated significantly with hepatic iron load (r = 0.8211, P < 0.001), but was substantially lower compared with wild-type controls. Duodenal ferroportin and divalent metal transporter 1 (DMT1), as well as splenic and hepatic ferroportin, were overexpressed in these animals. A high-iron diet (2% carbonyl iron) suppressed duodenal DMT1 levels in both wild-type and Hjv-/- mice; however, it did not affect duodenal ferroportin expression in Hjv-/- mice, and only reduced it in wild-type mice. In contrast, the high-iron diet decreased splenic ferroportin exclusively in Hjv-/- mice, whereas it induced hepatic ferroportin exclusively in wild-type mice. Conclusion: Our data show that dietary iron differentially affects ferroportin expression in mouse tissues and are consistent with hepcidin-dependent and hepcidin-independent mechanisms for ferroportin regulation. In the Hjv-/- mouse model of hemochromatosis, duodenal ferroportin remains unresponsive to iron but DMT1 is appropriately iron-regulated.


Asunto(s)
Proteínas de Transporte de Catión/metabolismo , Hemocromatosis/metabolismo , Hierro de la Dieta/farmacología , Hierro/metabolismo , Animales , Modelos Animales de Enfermedad , Duodeno/efectos de los fármacos , Hepcidinas/metabolismo , Hígado/efectos de los fármacos , Ratones , Bazo/efectos de los fármacos
9.
Am J Physiol Gastrointest Liver Physiol ; 321(3): G325-G334, 2021 09 01.
Artículo en Inglés | MEDLINE | ID: mdl-34231391

RESUMEN

Bisacodyl is a stimulant laxative often used in manometric studies of pediatric constipation to determine if it can initiate propulsive high-amplitude propagating contractions (HAPCs). Whereas the effects of bisacodyl infusion on colonic motility are well described, the effects of the drug on other regions of the gut after colonic infusion are not known. The aim of the present study was to characterize the effects of bisacodyl on both colonic and small bowel motility. Twenty-seven children (9.3 ± 1.2 yr) undergoing simultaneous high-resolution antroduodenal and colonic manometry were included. Small bowel and colonic motor patterns were assessed before and after colonic infusion of bisacodyl. Patients were divided into two groups: responders and nonresponders based on the presence of high-amplitude propagating contractions (HAPCs) after bisacodyl infusion. Nineteen patients were responders. A total of 188 postbisacodyl HAPCs was identified with a mean count of 10.4 ± 5.5 (range, 3-22), at a frequency of 0.6 ± 0.2/min and mean amplitude of 119.8 ± 23.6 mmHg. No motor patterns were induced in the small bowel. However, in the 19 responders the onset of HAPCs was associated with a significant decrease in small bowel contractile activity. In the nonresponders, there was no detectable change in small bowel motility after bisacodyl infusion. Bisacodyl-induced HAPCs are associated with a significant reduction in small bowel motility probably mediated by extrinsic sympathetic reflex pathways. This inhibition is potentially related to rectal distension, caused by the HAPC anal propulsion of colonic content.NEW & NOTEWORTHY The present study has shown, for the first time, that the presence of high-amplitude propagating contractions induced by bisacodyl is associated with a significant reduction in small bowel motility. These findings support of possible existence of a reflex pathway that causes inhibition of small bowel motility in response to rectal distension.


Asunto(s)
Bisacodilo/farmacología , Motilidad Gastrointestinal/efectos de los fármacos , Yeyuno/efectos de los fármacos , Contracción Muscular/efectos de los fármacos , Colon/efectos de los fármacos , Estreñimiento/tratamiento farmacológico , Duodeno/efectos de los fármacos , Motilidad Gastrointestinal/fisiología , Humanos , Laxativos/uso terapéutico , Contracción Muscular/fisiología , Enfermedades de la Vejiga Urinaria/tratamiento farmacológico
10.
Toxicol Appl Pharmacol ; 422: 115561, 2021 07 01.
Artículo en Inglés | MEDLINE | ID: mdl-33957193

RESUMEN

Arsenic is a global health concern that causes toxicity through ingestion of contaminated water and food. In vitro studies suggest that arsenic reduces stem and progenitor cell differentiation. Thus, this study determined if arsenic disrupted intestinal stem cell (ISC) differentiation, thereby altering the number, location, and/or function of intestinal epithelial cells. Adult male C57BL/6 mice were exposed to 0 or 100 ppb sodium arsenite (AsIII) through drinking water for 5 weeks. Duodenal sections were collected to assess changes in morphology, proliferation, and cell types. qPCR analysis revealed a 40% reduction in Lgr5 transcripts, an ISC marker, in the arsenic-exposed mice, although there were no changes in the protein expression of Olfm4. Secretory cell-specific transcript markers of Paneth (Defa1), Goblet (Tff3), and secretory transit amplifying (Math1) cells were reduced by 51%, 44%, and 30% respectively, in the arsenic-exposed mice, indicating significant impacts on the Wnt-dependent differentiation pathway. Further, protein levels of phosphorylated ß-catenin were reduced in the arsenic-exposed mice, which increased the expression of Wnt-dependent transcripts CD44 and c-myc. PCA analysis, followed by MANOVA and regression analyses, revealed significant changes and correlations between Lgr5 and the transit amplifying (TA) cell markers Math1 and Hes1, which are in the secretory cell pathway. Similar comparisons between Math1 and Defa1 show that terminal differentiation into Paneth cells is also reduced in the arsenic-exposed mice. The data suggests that ISCs are not lost following arsenic exposure, but rather, specific Wnt-dependent progenitor cell formation and terminal differentiation in the small intestine is reduced.


Asunto(s)
Arsenitos/toxicidad , Diferenciación Celular/efectos de los fármacos , Duodeno/efectos de los fármacos , Células de Paneth/efectos de los fármacos , Receptores Acoplados a Proteínas G/metabolismo , Compuestos de Sodio/toxicidad , Células Madre/efectos de los fármacos , Animales , Factores de Transcripción con Motivo Hélice-Asa-Hélice Básico/genética , Factores de Transcripción con Motivo Hélice-Asa-Hélice Básico/metabolismo , Regulación hacia Abajo , Duodeno/metabolismo , Duodeno/patología , Masculino , Ratones Endogámicos C57BL , Células de Paneth/metabolismo , Células de Paneth/patología , Receptores Acoplados a Proteínas G/genética , Células Madre/metabolismo , Células Madre/patología , Factor Trefoil-3/genética , Factor Trefoil-3/metabolismo , Vía de Señalización Wnt , alfa-Defensinas/genética , alfa-Defensinas/metabolismo
12.
Am J Physiol Endocrinol Metab ; 321(1): E1-E10, 2021 07 01.
Artículo en Inglés | MEDLINE | ID: mdl-34029163

RESUMEN

Bitter tastants are recently introduced as potential hunger-suppressive compounds, the so-called "Bitter pill." However, the literature about bitter administration lacks consistency in methods and findings. We want to test whether hunger ratings and hormone plasma levels are affected by: 1) the site of administration: intragastrically (IG) or intraduodenally (ID), 2) the bitter tastant itself, quinine hydrochloride (QHCl) or denatonium benzoate (DB), and 3) the timing of infusion. Therefore, 14 healthy, female volunteers participated in a randomized, placebo-controlled six-visit crossover study. After an overnight fast, DB (1 µmol/kg), QHCl (10 µmol/kg), or placebo were given IG or ID via a nasogastric feeding tube. Blood samples were taken 10 min before administration and every 10 min after administration for a period of 2 h. Hunger was rated at the same time points on a visual analogue scale. ID bitter administration did not affect hunger sensations, motilin, or acyl-ghrelin release compared with its placebo infusion. IG QHCl infusion tended to suppress hunger increase, especially between 50 and 70 min after infusion, simultaneously with reduced motilin values. Here, acyl-ghrelin was not affected. IG DB did not affect hunger or motilin, however acyl-ghrelin levels were reduced 50-70 minutes after infusion. Plasma values of glucagon-like peptide 1 and cholecystokinin were too low to be properly detected or to have any physiological relevance. In conclusion, bitter tastants should be infused into the stomach to reduce hunger sensations and orexigenic gut peptides. QHCl has the best potential to reduce hunger sensations, and it should be infused 60 min before food intake.NEW & NOTEWORTHY Bitter tastants are a potential new weight-loss treatment. This is a noninvasive, easy approach, which should be received with considerable enthusiasm by the public. However, literature about bitter administration lacks consistency in methods and findings. We summarize how the compound should be given based on: the site of administration, the best bitter compound to use, and at what timing in respect to the meal. This paper is therefore a fundamental step to continue research toward the further development of the "bitter pill."


Asunto(s)
Duodeno/efectos de los fármacos , Hambre/efectos de los fármacos , Hormonas Peptídicas/sangre , Compuestos de Amonio Cuaternario/administración & dosificación , Quinina/administración & dosificación , Estómago/efectos de los fármacos , Colecistoquinina , Estudios Cruzados , Femenino , Ghrelina/sangre , Péptido 1 Similar al Glucagón , Humanos , Intubación Gastrointestinal , Motilina/sangre , Placebos , Método Simple Ciego , Gusto , Pérdida de Peso , Adulto Joven
13.
Brain ; 144(6): 1853-1868, 2021 07 28.
Artículo en Inglés | MEDLINE | ID: mdl-33880502

RESUMEN

Neuronal aggregates of misfolded alpha-synuclein protein are found in the brain and periphery of patients with Parkinson's disease. Braak and colleagues have hypothesized that the initial formation of misfolded alpha-synuclein may start in the gut, and then spread to the brain via peripheral autonomic nerves hereby affecting several organs, including the heart and intestine. Age is considered the greatest risk factor for Parkinson's disease, but the effect of age on the formation of pathology and its propagation has not been studied in detail. We aimed to investigate whether propagation of alpha-synuclein pathology from the gut to the brain is more efficient in old versus young wild-type rats, upon gastrointestinal injection of aggregated alpha-synuclein. Our results demonstrate a robust age-dependent gut-to-brain and brain-to-gut spread of alpha-synuclein pathology along the sympathetic and parasympathetic nerves, resulting in age-dependent dysfunction of the heart and stomach, as observed in patients with Parkinson's disease. Moreover, alpha-synuclein pathology is more densely packed and resistant to enzymatic digestion in old rats, indicating an age-dependent maturation of alpha-synuclein aggregates. Our study is the first to provide a detailed investigation of alpha-synuclein pathology in several organs within one animal model, including the brain, skin, heart, intestine, spinal cord and autonomic ganglia. Taken together, our findings suggest that age is a crucial factor for alpha-synuclein aggregation and complete propagation to heart, stomach and skin, similar to patients. Given that age is the greatest risk factor for human Parkinson's disease, it seems likely that older experimental animals will yield the most relevant and reliable findings. These results have important implications for future research to optimize diagnostics and therapeutics in Parkinson's disease and other age-associated synucleinopathies. Increased emphasis should be placed on using aged animals in preclinical studies and to elucidate the nature of age-dependent interactions.


Asunto(s)
Envejecimiento/patología , Disautonomías Primarias/etiología , alfa-Sinucleína/toxicidad , Envejecimiento/metabolismo , Animales , Sistema Nervioso Autónomo/efectos de los fármacos , Sistema Nervioso Autónomo/metabolismo , Sistema Nervioso Autónomo/patología , Encéfalo/patología , Duodeno/efectos de los fármacos , Duodeno/patología , Riñón/patología , Músculo Esquelético/patología , Miocardio/patología , Enfermedad de Parkinson/metabolismo , Enfermedad de Parkinson/patología , Disautonomías Primarias/metabolismo , Disautonomías Primarias/patología , Agregación Patológica de Proteínas/patología , Ratas Endogámicas F344 , Piel/patología , Médula Espinal/patología , Estómago/efectos de los fármacos , Estómago/patología
14.
Neurotox Res ; 39(3): 800-814, 2021 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-33689147

RESUMEN

The enteric nervous system is responsible for controlling the gastrointestinal tract (GIT) functions. Enteric neuropathies are highly correlated to the development of several intestinal disturbances. Fluoride (F) is extensively applied for dental health improvement and its ingestion can promote systemic toxicity with mild to severe GIT symptomatology and neurotoxicity. Although F harmful effects have been published, there is no information regarding noxiousness of a high acute F exposure (25 mg F/kg) on enteric neurons and levels of expression of intestinal proteins in the duodenum. Quantitative proteomics of the duodenum wall associated to morphometric and quantitative analysis of enteric neurons displayed F effects of a high acute exposure. F-induced myenteric neuroplasticity was characterized by a decrease in the density of nitrergic neurons and morphometric alterations in the general populations of neurons, nitrergic neurons, and substance P varicosities. Proteomics demonstrated F-induced alterations in levels of expression of 356 proteins correlated to striated muscle cell differentiation; generation of precursor metabolites and energy; NADH and glutathione metabolic process and purine ribonucleoside triphosphate biosynthesis. The neurochemical role of several intestinal proteins was discussed specially related to the modulation of enteric neuroplasticity. The results provide a new perspective on cell signaling pathways of gastrointestinal symptomatology promoted by acute F toxicity.


Asunto(s)
Duodeno/efectos de los fármacos , Sistema Nervioso Entérico/efectos de los fármacos , Fluoruros/toxicidad , Neuronas/efectos de los fármacos , Mapas de Interacción de Proteínas/efectos de los fármacos , Proteómica/métodos , Animales , Duodeno/metabolismo , Sistema Nervioso Entérico/citología , Sistema Nervioso Entérico/metabolismo , Masculino , Neuronas/metabolismo , Mapas de Interacción de Proteínas/fisiología , Ratas , Ratas Wistar
15.
Tissue Cell ; 69: 101483, 2021 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-33444959

RESUMEN

Diabetes mellitus (DM) is a metabolic disease associated with several intestinal disorders. S-methyl cysteine sulfoxide (SMCS) ​​is an amino acid present in Allium cepa L with hypoglycemic effects. However, the effects of SMCS on diabetic intestinal changes are unknown. Thus, we aimed to investigate the effects of SMCS on duodenal morphology and immunomodulatory markers in diabetic rats. Twenty-six rats were divided into three groups: control (C), diabetic (D) and diabetic +200 mg/kg SMCS (DSM). DM was induced by intraperitoneal injection of streptozotocin (50 mg/kg). After 30 days, duodenum samples were processed to assess histopathological and stereological alterations in volume, villus length, and immunohistochemical expression of NF-kB, IL-10, BCL-2, and caspase-3. SMCS reduced hyperglycemia and mitigated the increase in total reference volume of the duodenum, the absolute volume of the mucosa, and the length of the intestinal crypts in the DMS group when compared to D. IL-10 immunostaining was reduced in D when compared to C, while NF-kB was increased in D in comparison to the other groups. SMCS ​​supplementation could decrease the NF-kB immunostaining observed in D. Positive staining for BCL-2 and caspase-3 were not statistically different between groups. In summary, SMCS decreased hyperglycemia and mitigated the morphological changes of the duodenum in diabetic animals, and these beneficial effects can be partially explained by NF-kB modulation.


Asunto(s)
Cisteína/análogos & derivados , Diabetes Mellitus Experimental/patología , Duodeno/patología , Animales , Peso Corporal/efectos de los fármacos , Cisteína/farmacología , Ingestión de Líquidos/efectos de los fármacos , Duodeno/efectos de los fármacos , Conducta Alimentaria/efectos de los fármacos , Masculino , Ratas Wistar
16.
J Food Sci ; 86(2): 540-545, 2021 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-31042819

RESUMEN

Sucralose (SUC) has been used in the food industry for nearly 30 years since it was first allowed as an artificial sweetener at the end of the 20th century. However, its effects on the body remain not incontrovertible. This work aimed to investigate the influence of SUC exposure on sweetness receptors and glucose absorption and to explore the relationship between them. Mice were exposed with different concentration of SUC (from 0.27 to 0.47 g/L) for 12 weeks. Long-term treatment with SUC resulted in impaired glucose metabolism, manifested in the decrease of glucose tolerance and the increase of sweet taste receptors, glucose transporters, and glucose absorption. This study also provides a method to quantify the glucose absorptivity. In detail, with increasing concentration of SUC, the glucose absorptivities in the dodecadactylon of mice were added 1.48, 1.56, 1.71, and 1.71 times, respectively, showing wide interindividual variation compared with the control group. PRACTICAL APPLICATION: The artificial sweetener, sucralose, has physiological influences of changing glucose metabolism. The small bowel is the main location for glucose metabolism and absorbs the ingested proteins and carbohydrates. And, this study provides a method to quantify the glucose absorptivity of intestine.


Asunto(s)
Duodeno/efectos de los fármacos , Duodeno/metabolismo , Glucosa/metabolismo , Sacarosa/análogos & derivados , Edulcorantes/farmacología , Gusto/fisiología , Animales , Regulación de la Expresión Génica/efectos de los fármacos , Hexosas , Ratones , Sacarosa/farmacología , Gusto/genética
18.
Can J Physiol Pharmacol ; 99(3): 270-277, 2021 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-32687730

RESUMEN

Sodium deoxycholate (NaDOC) inhibits the intestinal Ca2+ absorption and ursodeoxycholic acid (UDCA) stimulates it. The aim of this study was to determine whether NaDOC and UDCA produce differential effects on the redox state of duodenal mitochondria altering the Krebs cycle and the electron transport chain (ETC) functioning, which could lead to perturbations in the mitochondrial dynamics and biogenesis. Rat intestinal mitochondria were isolated from untreated and treated animals with either NaDOC, UDCA, or both. Krebs cycle enzymes, ETC components, ATP synthase, and mitochondrial dynamics and biogenesis markers were determined. NaDOC decreased isocitrate dehydrogenase (ICDH) and malate dehydrogenase activities affecting the ETC and ATP synthesis. NaDOC also induced oxidative stress and increased the superoxide dismutase activity and impaired the mitochondrial biogenesis and functionality. UDCA increased the activities of ICDH and complex II of ETC. The combination of both bile acids conserved the functional activities of Krebs cycle enzymes, ETC components, oxidative phosphorylation, and mitochondrial biogenesis. In conclusion, the inhibitory effect of NaDOC on intestinal Ca2+ absorption is mediated by mitochondrial dysfunction, which is avoided by UDCA. The stimulatory effect of UDCA alone is associated with amelioration of mitochondrial functioning. This knowledge could improve treatment of diseases that affect the intestinal Ca2+ absorption.


Asunto(s)
Colagogos y Coleréticos/farmacología , Ácido Desoxicólico/farmacología , Duodeno/efectos de los fármacos , Mitocondrias/metabolismo , Ácido Ursodesoxicólico/farmacología , Animales , Calcio/farmacocinética , Colagogos y Coleréticos/farmacocinética , Ciclo del Ácido Cítrico/efectos de los fármacos , Ácido Desoxicólico/farmacocinética , Transporte de Electrón , Absorción Intestinal/efectos de los fármacos , Masculino , ATPasas de Translocación de Protón Mitocondriales/metabolismo , Biogénesis de Organelos , Fosforilación Oxidativa/efectos de los fármacos , Estrés Oxidativo , Ratas , Ratas Wistar , Superóxido Dismutasa/metabolismo , Ácido Ursodesoxicólico/farmacocinética
19.
J Biol Chem ; 296: 100195, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-33334885

RESUMEN

Iron is an essential metal for all living organisms that is absorbed in the intestinal cells as a heme-chelated or free form. It is unclear how important plant-derived chelators, such as nicotianamine (NA), an organic small molecule that is ubiquitous in crops, vegetables, and various other foods, contribute to iron bioavailability in mammals. We performed electrophysiological assays with Xenopus laevis oocytes and radioactive tracer experiments with Caco-2 cells. The findings revealed that the proton-coupled amino acid transporter SLC36A1 (PAT1) transports iron in the form of NA-Fe (II) complex in vitro. Decreased expression of hPAT1 by RNA interference in Caco-2 cells reduced the uptake of NA-59Fe (II) complex. The uptake of inorganic 59Fe (II) was relatively unaffected. These results imply that PAT1 transports iron as a NA-Fe (II) complex. The rate of 59Fe absorption in the spleen, liver, and kidney was higher when mice were orally administered NA-59Fe (II) compared with free 59Fe (II). The profile of site-specific PAT1 expression in the mouse intestine coincided with those of NA and iron contents, which were the highest in the proximal jejunum. Orally administered NA-59Fe (II) complex in mice was detected in the proximal jejunum by thin layer chromatography. In contrast, much less 59Fe (or NA) was detected in the duodenum, where the divalent metal transporter SLC11A2 (DMT1) absorbs free Fe (II). The collective results revealed the role of PAT1 in NA-Fe (II) absorption in the intestine and potential implication of NA in iron uptake in mammals.


Asunto(s)
Ácido Azetidinocarboxílico/análogos & derivados , Quelantes/farmacología , Intestino Delgado/efectos de los fármacos , Intestino Delgado/metabolismo , Hierro/metabolismo , Animales , Ácido Azetidinocarboxílico/farmacología , Disponibilidad Biológica , Transporte Biológico/efectos de los fármacos , Células Cultivadas , Duodeno/efectos de los fármacos , Duodeno/metabolismo , Humanos , Absorción Intestinal/efectos de los fármacos , Yeyuno/efectos de los fármacos , Yeyuno/metabolismo , Masculino , Ratones , Ratones Endogámicos ICR , Fitoquímicos/farmacología , Xenopus laevis
20.
Gastroenterology ; 160(5): 1521-1531.e9, 2021 04.
Artículo en Inglés | MEDLINE | ID: mdl-33346007

RESUMEN

BACKGROUND & AIMS: Despite the growing recognition of duodenal alterations in the pathophysiology of functional dyspepsia (FD), the effect and mechanism of proton pump inhibitors (PPIs) or first-line therapy remain unclear. We studied duodenal and systemic alterations in relation to PPI therapy in patients with FD and healthy volunteers (HVs). METHODS: We performed a prospective interventional study assessing symptoms (Patient Assessment of Gastrointestinal Symptom Severity Index), duodenal alterations, and systemic factors in patients with FD ("FD-starters") and HVs before and after PPI therapy (pantoprazole 40 mg once daily for 4 weeks). Duodenal mucosal eosinophils, mast cells and permeability were quantified. Luminal pH and bile salts were determined in duodenal aspirates. Procedures were also performed in PPI-refractory patients with FD ("FD-stoppers") before and 8 weeks after PPI withdrawal. Between- and within-group changes from baseline and associations with duodenal or systemic factors were analyzed using linear mixed models. RESULTS: The study was completed by 30 HV, 27 FD-starters, and 18 FD-stoppers. Symptoms and duodenal eosinophils, mast cells (all, P < .0001), and paracellular passage (P = .02) were significantly higher in FD-starters vs HVs and reduced with PPI therapy. Symptoms and duodenal immune cells also decreased in FD-stoppers off PPIs. In contrast, immune cells and permeability increased in HVs on PPIs. Dyspeptic symptoms correlated with eosinophils before and during PPI therapy, and increased eosinophils and permeability in HVs on PPIs were associated with changes in bile salts. CONCLUSIONS: We provide the first prospective evidence for eosinophil-reducing effects as a therapeutic mechanism of PPIs in FD, with differential effects in HVs pointing to a role of luminal changes. ClinicalTrials.gov, Number: NCT03545243.


Asunto(s)
Enfermedades Duodenales/tratamiento farmacológico , Duodeno/efectos de los fármacos , Dispepsia/tratamiento farmacológico , Eosinofilia/tratamiento farmacológico , Enfermedades Inflamatorias del Intestino/tratamiento farmacológico , Mucosa Intestinal/efectos de los fármacos , Mastocitos/efectos de los fármacos , Pantoprazol/uso terapéutico , Inhibidores de la Bomba de Protones/uso terapéutico , Adulto , Bélgica , Ácidos y Sales Biliares/metabolismo , Estudios de Casos y Controles , Enfermedades Duodenales/diagnóstico , Enfermedades Duodenales/inmunología , Enfermedades Duodenales/metabolismo , Duodeno/inmunología , Duodeno/metabolismo , Dispepsia/diagnóstico , Dispepsia/inmunología , Dispepsia/metabolismo , Eosinofilia/diagnóstico , Eosinofilia/inmunología , Eosinofilia/metabolismo , Femenino , Humanos , Mediadores de Inflamación/metabolismo , Enfermedades Inflamatorias del Intestino/diagnóstico , Enfermedades Inflamatorias del Intestino/inmunología , Enfermedades Inflamatorias del Intestino/metabolismo , Mucosa Intestinal/inmunología , Mucosa Intestinal/metabolismo , Masculino , Mastocitos/inmunología , Mastocitos/metabolismo , Pantoprazol/efectos adversos , Permeabilidad , Estudios Prospectivos , Inhibidores de la Bomba de Protones/efectos adversos , Factores de Tiempo , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA